540 related articles for article (PubMed ID: 23741487)
1. The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell.
Yang Y; Li H; Hou S; Hu B; Liu J; Wang J
PLoS One; 2013; 8(5):e65309. PubMed ID: 23741487
[TBL] [Abstract][Full Text] [Related]
2. Long noncoding RNA AK126698 inhibits proliferation and migration of non-small cell lung cancer cells by targeting Frizzled-8 and suppressing Wnt/β-catenin signaling pathway.
Fu X; Li H; Liu C; Hu B; Li T; Wang Y
Onco Targets Ther; 2016; 9():3815-27. PubMed ID: 27445486
[TBL] [Abstract][Full Text] [Related]
3. LncRNA XIST acts as a MicroRNA-520 sponge to regulate the Cisplatin resistance in NSCLC cells by mediating BAX through CeRNA network.
Liu TT; Li R; Liu X; Zhou XJ; Huo C; Li JP; Qu YQ
Int J Med Sci; 2021; 18(2):419-431. PubMed ID: 33390811
[No Abstract] [Full Text] [Related]
4. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin and phenanthriplatin modulate long-noncoding RNA expression in A549 and IMR90 cells revealing regulation of microRNAs, Wnt/β-catenin and TGF-β signaling.
Monroe JD; Moolani SA; Irihamye EN; Lett KE; Hebert MD; Gibert Y; Smith ME
Sci Rep; 2021 May; 11(1):10408. PubMed ID: 34001990
[TBL] [Abstract][Full Text] [Related]
6. Microarray data re-annotation reveals specific lncRNAs and their potential functions in non-small cell lung cancer subtypes.
Zhou D; Xie M; He B; Gao Y; Yu Q; He B; Chen Q
Mol Med Rep; 2017 Oct; 16(4):5129-5136. PubMed ID: 28849055
[TBL] [Abstract][Full Text] [Related]
7. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
Cai Y; Dong ZY; Wang JY
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
[TBL] [Abstract][Full Text] [Related]
8. Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway.
Ma LY; Xie XW; Ma L; Pang JL; Xiong XM; Zheng HD; Shen XL; Wen ZG; Wang HY
Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2626-2634. PubMed ID: 28678322
[TBL] [Abstract][Full Text] [Related]
9. LncRNA SNHG14 regulates the DDP-resistance of non-small cell lung cancer cell through miR-133a/HOXB13 pathway.
Xu L; Xu Y; Yang M; Li J; Xu F; Chen BL
BMC Pulm Med; 2020 Oct; 20(1):266. PubMed ID: 33059643
[TBL] [Abstract][Full Text] [Related]
10. NEAT1 contributes to the CSC-like traits of A549/CDDP cells via activating Wnt signaling pathway.
Jiang P; Xu H; Xu C; Chen A; Chen L; Zhou M; Haq IU; Wu X; Mariyam Z; Feng Q
Chem Biol Interact; 2018 Dec; 296():154-161. PubMed ID: 30291867
[TBL] [Abstract][Full Text] [Related]
11. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/β-catenin signaling pathway.
Xia Y; He Z; Liu B; Wang P; Chen Y
Mol Med Rep; 2015 Sep; 12(3):4530-4537. PubMed ID: 26059239
[TBL] [Abstract][Full Text] [Related]
13. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer.
Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ
Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469
[TBL] [Abstract][Full Text] [Related]
14. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
Gao BB; Wang SX
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
[TBL] [Abstract][Full Text] [Related]
15. Aberrant Long Noncoding RNAs Expression Profiles Affect Cisplatin Resistance in Lung Adenocarcinoma.
Hu L; Chen J; Zhang F; Wang J; Pan J; Chen J; Wang Y
Biomed Res Int; 2017; 2017():7498151. PubMed ID: 29279851
[TBL] [Abstract][Full Text] [Related]
16. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis.
Wang L; Shang X; Feng Q
Cancer Biol Ther; 2019; 20(3):261-271. PubMed ID: 30481109
[TBL] [Abstract][Full Text] [Related]
17. Silence of fibronectin 1 increases cisplatin sensitivity of non-small cell lung cancer cell line.
Gao W; Liu Y; Qin R; Liu D; Feng Q
Biochem Biophys Res Commun; 2016 Jul; 476(1):35-41. PubMed ID: 27207836
[TBL] [Abstract][Full Text] [Related]
18. Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer.
Cheng N; Li X; Zhao C; Ren S; Chen X; Cai W; Zhao M; Zhang Y; Li J; Wang Q; Zhou C
Oncol Rep; 2015 Feb; 33(2):833-9. PubMed ID: 25482516
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of lncRNA-XIST enhances the chemosensitivity of NSCLC cells via suppression of autophagy.
Sun W; Zu Y; Fu X; Deng Y
Oncol Rep; 2017 Dec; 38(6):3347-3354. PubMed ID: 29130102
[TBL] [Abstract][Full Text] [Related]
20. LncRNA XIST promotes human lung adenocarcinoma cells to cisplatin resistance via let-7i/BAG-1 axis.
Sun J; Pan LM; Chen LB; Wang Y
Cell Cycle; 2017; 16(21):2100-2107. PubMed ID: 28961027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
